Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age

What Was Tested

This randomized controlled trial paper looks at Leuprolide.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, men only.

The EMBARK trial (NCT02319837) included patients with hrBCR after local therapy, prostate-specific antigen (PSA) doubling time ≤ 9 months, and PSA ≥ 2 ng/mL above nadir post radiotherapy (RT) or ≥ 1 ng/mL after radical prostatectomy ± postoperative RT.

Patients were randomized (1:1:1) to enzalutamide with leuprolide (combination), leuprolide and placebo (leuprolide alone), or enzalutamide alone (monotherapy).

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Leuprolide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Leuprolide group a baseline to be compared against.

This analysis compares MFS and safety outcomes by age group (<70 vs ≥70 years).

What Was Measured

Topics PubMed links to this paper include Leuprolide, Nitriles, Phenylthiohydantoin, Benzamides, Age Factors, Neoplasm Recurrence, Local and Prostatic Neoplasms.

The authors tagged it with the keywords Age groups, Androgen receptor antagonist, Antineoplastic hormonal agents, Enzalutamide, Leuprolide acetate and Prostate-specific antigen.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Leuprolide.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (European journal of cancer (Oxford, England : 1990)), a journal based in England.

More context: the Leuprolide compound page, all human trials.